Switch to:
Also traded in: Argentina, Germany, Mexico, Sweden, Switzerland, UK, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.35
AZN's Cash-to-Debt is ranked lower than
76% of the 733 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.95 vs. AZN: 0.35 )
Ranked among companies with meaningful Cash-to-Debt only.
AZN' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.35  Med: 2.15 Max: 8.68
Current: 0.35
0.35
8.68
Equity-to-Asset 0.24
AZN's Equity-to-Asset is ranked lower than
90% of the 676 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.62 vs. AZN: 0.24 )
Ranked among companies with meaningful Equity-to-Asset only.
AZN' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.24  Med: 0.44 Max: 0.59
Current: 0.24
0.24
0.59
Interest Coverage 8.07
AZN's Interest Coverage is ranked lower than
76% of the 721 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 88.12 vs. AZN: 8.07 )
Ranked among companies with meaningful Interest Coverage only.
AZN' s Interest Coverage Range Over the Past 10 Years
Min: 5.11  Med: 8.2 Max: 19.13
Current: 8.07
5.11
19.13
Piotroski F-Score: 6
Altman Z-Score: 1.68
Beneish M-Score: -2.68
WACC vs ROIC
8.19%
18.11%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % 22.02
AZN's Operating Margin % is ranked higher than
83% of the 686 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.19 vs. AZN: 22.02 )
Ranked among companies with meaningful Operating Margin % only.
AZN' s Operating Margin % Range Over the Past 10 Years
Min: 8.19  Med: 28.16 Max: 38.09
Current: 22.02
8.19
38.09
Net Margin % 15.83
AZN's Net Margin % is ranked higher than
80% of the 687 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.80 vs. AZN: 15.83 )
Ranked among companies with meaningful Net Margin % only.
AZN' s Net Margin % Range Over the Past 10 Years
Min: 4.73  Med: 19.12 Max: 29.72
Current: 15.83
4.73
29.72
ROE % 24.95
AZN's ROE % is ranked higher than
87% of the 703 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.86 vs. AZN: 24.95 )
Ranked among companies with meaningful ROE % only.
AZN' s ROE % Range Over the Past 10 Years
Min: 5.9  Med: 31.4 Max: 45.52
Current: 24.95
5.9
45.52
ROA % 5.90
AZN's ROA % is ranked higher than
63% of the 735 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.38 vs. AZN: 5.90 )
Ranked among companies with meaningful ROA % only.
AZN' s ROA % Range Over the Past 10 Years
Min: 2.2  Med: 12.84 Max: 18.34
Current: 5.9
2.2
18.34
ROC (Joel Greenblatt) % 66.64
AZN's ROC (Joel Greenblatt) % is ranked higher than
89% of the 724 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 13.39 vs. AZN: 66.64 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
AZN' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 28.78  Med: 119.25 Max: 199.64
Current: 66.64
28.78
199.64
3-Year Revenue Growth Rate 5.10
AZN's 3-Year Revenue Growth Rate is ranked lower than
53% of the 604 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.70 vs. AZN: 5.10 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
AZN' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -5.8  Med: 5.1 Max: 19.9
Current: 5.1
-5.8
19.9
3-Year EBITDA Growth Rate 0.90
AZN's 3-Year EBITDA Growth Rate is ranked lower than
67% of the 577 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.20 vs. AZN: 0.90 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
AZN' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -30.6  Med: 10.1 Max: 24.8
Current: 0.9
-30.6
24.8
3-Year EPS without NRI Growth Rate 21.10
AZN's 3-Year EPS without NRI Growth Rate is ranked higher than
70% of the 548 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.30 vs. AZN: 21.10 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
AZN' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -48.9  Med: 12.4 Max: 24.7
Current: 21.1
-48.9
24.7
GuruFocus has detected 7 Warning Signs with AstraZeneca PLC $AZN.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» AZN's 10-Y Financials

Financials (Next Earnings Date: 2017-05-02 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

AZN Guru Trades in Q1 2016

Jeremy Grantham 408,300 sh (New)
PRIMECAP Management 13,084,275 sh (+1223.11%)
Dodge & Cox 26,049,650 sh (+121.19%)
Jim Simons 5,682,800 sh (+14.58%)
Manning & Napier Advisors, Inc 487,770 sh (+6.07%)
Ken Fisher 233,409 sh (+5.33%)
Murray Stahl 28,302 sh (+1.08%)
John Hussman 2,000 sh (unchged)
Francis Chou 13,000 sh (unchged)
NWQ Managers 506,785 sh (-1.83%)
Pioneer Investments 446,513 sh (-79.72%)
» More
Q2 2016

AZN Guru Trades in Q2 2016

David Dreman 1,321 sh (New)
Ken Fisher 338,979 sh (+45.23%)
Jeremy Grantham 587,200 sh (+43.82%)
Dodge & Cox 32,532,723 sh (+24.89%)
PRIMECAP Management 15,365,950 sh (+17.44%)
NWQ Managers 572,985 sh (+13.06%)
Jim Simons 5,966,100 sh (+4.99%)
Pioneer Investments 447,226 sh (+0.16%)
Murray Stahl 28,302 sh (unchged)
John Hussman 2,000 sh (unchged)
Francis Chou 13,000 sh (unchged)
Manning & Napier Advisors, Inc 487,770 sh (unchged)
» More
Q3 2016

AZN Guru Trades in Q3 2016

Andreas Halvorsen 4,175,587 sh (New)
Ken Fisher 1,977,585 sh (+483.39%)
NWQ Managers 839,815 sh (+46.57%)
Dodge & Cox 42,189,973 sh (+29.68%)
PRIMECAP Management 17,313,325 sh (+12.67%)
Manning & Napier Advisors, Inc 495,960 sh (+1.68%)
Jeremy Grantham 594,800 sh (+1.29%)
John Hussman 2,000 sh (unchged)
Francis Chou 13,000 sh (unchged)
David Dreman 1,321 sh (unchged)
Murray Stahl 28,302 sh (unchged)
Pioneer Investments 446,742 sh (-0.11%)
Jim Simons 5,702,700 sh (-4.41%)
» More
Q4 2016

AZN Guru Trades in Q4 2016

Sarah Ketterer 514,612 sh (New)
Steven Cohen 676,000 sh (New)
Pioneer Investments 1,194,403 sh (+167.36%)
PRIMECAP Management 25,980,275 sh (+50.06%)
Dodge & Cox 49,613,588 sh (+17.60%)
NWQ Managers 945,170 sh (+12.55%)
Murray Stahl 28,302 sh (unchged)
Francis Chou 13,000 sh (unchged)
Manning & Napier Advisors, Inc 495,960 sh (unchged)
John Hussman 2,000 sh (unchged)
Ken Fisher 1,950,999 sh (-1.34%)
Andreas Halvorsen 2,859,129 sh (-31.53%)
Jeremy Grantham 240,631 sh (-59.54%)
Jim Simons 1,394,800 sh (-75.54%)
David Dreman 180 sh (-86.37%)
» More
» Details

Insider Trades

Latest Guru Trades with AZN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major    NAICS: 325412 
Compare:NYSE:LLY, NYSE:BMY, OTCPK:BAYRY, NYSE:ABBV, OTCPK:GLAXF, NYSE:SNY, OTCPK:ALPMY, OTCPK:OTSKY, OTCPK:CHGCF, OTCPK:DSNKY, OTCPK:OPHLY, OTCPK:SNPHY, OTCPK:PTKFY, NAS:GWPH, NAS:HCM, OTCPK:BOIRF, NAS:AERI, OTCPK:HAWPF, OTCPK:MAYNF, OTCPK:VEGPF » details
Traded in other countries:AZN.Argentina, ZEG.Germany, AZNN.Mexico, AZN.Sweden, AZN.Switzerland, AZN.UK, AZNCF.USA,
AstraZeneca PLC is a biopharmaceutical company. It is engaged in the discovery and development of new products, which are then manufactured, marketed and sold.

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The company sells branded drugs across several major therapeutic classes, including gastrointestinal, cardiovascular, respiratory, cancer, immunology, and neuroscience. The majority of sales come from international markets with the United States representing slightly less than 40% of its sales.

Guru Investment Theses on AstraZeneca PLC

Dodge & Cox Comments on AstraZeneca - Feb 06, 2017

AstraZeneca (NYSE:AZN), which is based in the United Kingdom, is a global pharmaceutical company with strengths in treatment for cancer and respiratory, cardiovascular, and infectious diseases. The share price has been under pressure due to recent and upcoming patent expirations for major drugs. Despite this headwind, the long-term growth outlook is favorable because of the company’s robust new drug pipeline, particularly in oncology. AstraZeneca has an attractive position in the revolutionary field of cancer immunotherapy, which harnesses the disease -fighting capabilities of the body’s immune system to reduce and potentially eliminate cancer tumors. With a 4.6% dividend yield, the current valuation is reasonable and does not appear to reflect the potential success of the immunotherapy drug pipeline.





From Dodge & Cox's Global Stock Fund 4th quarter 2016 shareholder letter.



Check out Dodge & Cox latest stock trades

Top Ranked Articles about AstraZeneca PLC

Dodge & Cox Comments on AstraZeneca Guru stock highlight
AstraZeneca (NYSE:AZN), which is based in the United Kingdom, is a global pharmaceutical company with strengths in treatment for cancer and respiratory, cardiovascular, and infectious diseases. The share price has been under pressure due to recent and upcoming patent expirations for major drugs. Despite this headwind, the long-term growth outlook is favorable because of the company’s robust new drug pipeline, particularly in oncology. AstraZeneca has an attractive position in the revolutionary field of cancer immunotherapy, which harnesses the disease -fighting capabilities of the body’s immune system to reduce and potentially eliminate cancer tumors. With a 4.6% dividend yield, the current valuation is reasonable and does not appear to reflect the potential success of the immunotherapy drug pipeline. Read more...
Big Alzheimer Flop Creates Buying Opportunity for Eli Lilly Eli Lilly has new drugs in the pipeline that will replace its failed Alzheimer treatment
Eli Lilly (NYSE:LLY) made the news for the wrong reasons on Nov. 23 after announcing that its experimental treatment for Alzheimer’s drug, Solanezumab, had failed. If it had been successful, Eli Lilly would have the distinction of researching the first effective disease modifying drug in the world. Read more...
How Could a Potential Nexium Lawsuit Affect AstraZeneca? Company's top line could suffer significantly if Nexium sales are affected by lawsuit
AstraZeneca (NYSE:AZN) is the company behind Nexium, one of the world’s most successful drugs in terms of sales. Nexium, the brand name of esomeprazole, is a proton-pump inhibitor that reduces stomach acid. It was developed in the 1990s for the purpose of treating dyspepsia, peptic ulcer disease, gastroesophageal reflux disease and Zollinger-Ellison syndrome. Read more...

Ratios

vs
industry
vs
history
PE Ratio 23.36
AZN's PE Ratio is ranked higher than
61% of the 717 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.26 vs. AZN: 23.36 )
Ranked among companies with meaningful PE Ratio only.
AZN' s PE Ratio Range Over the Past 10 Years
Min: 6.03  Med: 12.36 Max: 99.64
Current: 23.36
6.03
99.64
Forward PE Ratio 16.95
AZN's Forward PE Ratio is ranked higher than
53% of the 109 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 18.08 vs. AZN: 16.95 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 23.36
AZN's PE Ratio without NRI is ranked higher than
62% of the 595 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.28 vs. AZN: 23.36 )
Ranked among companies with meaningful PE Ratio without NRI only.
AZN' s PE Ratio without NRI Range Over the Past 10 Years
Min: 6.03  Med: 12.36 Max: 99.64
Current: 23.36
6.03
99.64
Price-to-Owner-Earnings 18.28
AZN's Price-to-Owner-Earnings is ranked higher than
73% of the 302 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 33.92 vs. AZN: 18.28 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
AZN' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 5.38  Med: 11.65 Max: 45.27
Current: 18.28
5.38
45.27
PB Ratio 5.29
AZN's PB Ratio is ranked lower than
75% of the 898 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.82 vs. AZN: 5.29 )
Ranked among companies with meaningful PB Ratio only.
AZN' s PB Ratio Range Over the Past 10 Years
Min: 2.3  Med: 3.82 Max: 6.97
Current: 5.29
2.3
6.97
PS Ratio 3.69
AZN's PS Ratio is ranked lower than
59% of the 867 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.76 vs. AZN: 3.69 )
Ranked among companies with meaningful PS Ratio only.
AZN' s PS Ratio Range Over the Past 10 Years
Min: 1.61  Med: 2.41 Max: 4.03
Current: 3.69
1.61
4.03
Price-to-Free-Cash-Flow 43.72
AZN's Price-to-Free-Cash-Flow is ranked lower than
65% of the 291 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 25.25 vs. AZN: 43.72 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
AZN' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 6.18  Med: 14.07 Max: 179.65
Current: 43.72
6.18
179.65
Price-to-Operating-Cash-Flow 19.98
AZN's Price-to-Operating-Cash-Flow is ranked lower than
54% of the 369 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.28 vs. AZN: 19.98 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
AZN' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 5.35  Med: 8.7 Max: 33.31
Current: 19.98
5.35
33.31
EV-to-EBIT 22.57
AZN's EV-to-EBIT is ranked lower than
59% of the 767 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.12 vs. AZN: 22.57 )
Ranked among companies with meaningful EV-to-EBIT only.
AZN' s EV-to-EBIT Range Over the Past 10 Years
Min: 4.3  Med: 8.6 Max: 64.7
Current: 22.57
4.3
64.7
EV-to-EBITDA 14.61
AZN's EV-to-EBITDA is ranked higher than
51% of the 783 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 14.99 vs. AZN: 14.61 )
Ranked among companies with meaningful EV-to-EBITDA only.
AZN' s EV-to-EBITDA Range Over the Past 10 Years
Min: 3.6  Med: 6.9 Max: 20.9
Current: 14.61
3.6
20.9
Shiller PE Ratio 18.74
AZN's Shiller PE Ratio is ranked higher than
85% of the 164 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 44.73 vs. AZN: 18.74 )
Ranked among companies with meaningful Shiller PE Ratio only.
AZN' s Shiller PE Ratio Range Over the Past 10 Years
Min: 10  Med: 13.53 Max: 20.31
Current: 18.74
10
20.31
Current Ratio 0.87
AZN's Current Ratio is ranked lower than
91% of the 629 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.38 vs. AZN: 0.87 )
Ranked among companies with meaningful Current Ratio only.
AZN' s Current Ratio Range Over the Past 10 Years
Min: 0.87  Med: 1.49 Max: 2.01
Current: 0.87
0.87
2.01
Quick Ratio 0.72
AZN's Quick Ratio is ranked lower than
86% of the 628 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.75 vs. AZN: 0.72 )
Ranked among companies with meaningful Quick Ratio only.
AZN' s Quick Ratio Range Over the Past 10 Years
Min: 0.72  Med: 1.22 Max: 1.69
Current: 0.72
0.72
1.69
Days Inventory 202.19
AZN's Days Inventory is ranked lower than
83% of the 642 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 115.23 vs. AZN: 202.19 )
Ranked among companies with meaningful Days Inventory only.
AZN' s Days Inventory Range Over the Past 10 Years
Min: 88.45  Med: 122.03 Max: 202.19
Current: 202.19
88.45
202.19
Days Sales Outstanding 44.30
AZN's Days Sales Outstanding is ranked higher than
79% of the 587 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 77.21 vs. AZN: 44.30 )
Ranked among companies with meaningful Days Sales Outstanding only.
AZN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 40.99  Med: 68.49 Max: 95.12
Current: 44.3
40.99
95.12
Days Payable 285.08
AZN's Days Payable is ranked higher than
95% of the 540 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 73.13 vs. AZN: 285.08 )
Ranked among companies with meaningful Days Payable only.
AZN' s Days Payable Range Over the Past 10 Years
Min: 130.53  Med: 186.12 Max: 397.09
Current: 285.08
130.53
397.09

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 4.41
AZN's Dividend Yield % is ranked higher than
95% of the 656 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.53 vs. AZN: 4.41 )
Ranked among companies with meaningful Dividend Yield % only.
AZN' s Dividend Yield % Range Over the Past 10 Years
Min: 2.22  Med: 4.58 Max: 7.64
Current: 4.41
2.22
7.64
Dividend Payout Ratio 1.01
AZN's Dividend Payout Ratio is ranked lower than
89% of the 406 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.35 vs. AZN: 1.01 )
Ranked among companies with meaningful Dividend Payout Ratio only.
AZN' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.4  Med: 0.56 Max: 2.89
Current: 1.01
0.4
2.89
3-Year Dividend Growth Rate 7.80
AZN's 3-Year Dividend Growth Rate is ranked lower than
51% of the 286 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.10 vs. AZN: 7.80 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
AZN' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: -4.5  Med: 9.5 Max: 28.3
Current: 7.8
-4.5
28.3
Forward Dividend Yield % 6.07
AZN's Forward Dividend Yield % is ranked higher than
98% of the 646 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.60 vs. AZN: 6.07 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 4.73
AZN's 5-Year Yield-on-Cost % is ranked higher than
86% of the 786 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.19 vs. AZN: 4.73 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
AZN' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 2.38  Med: 4.91 Max: 8.19
Current: 4.73
2.38
8.19
3-Year Average Share Buyback Ratio -0.20
AZN's 3-Year Average Share Buyback Ratio is ranked higher than
78% of the 446 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.00 vs. AZN: -0.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
AZN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -22.4  Med: 1.8 Max: 4.9
Current: -0.2
-22.4
4.9

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 2.04
AZN's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
59% of the 422 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.49 vs. AZN: 2.04 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
AZN' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.55  Med: 1.41 Max: 5.67
Current: 2.04
0.55
5.67
Price-to-Median-PS-Value 1.54
AZN's Price-to-Median-PS-Value is ranked lower than
72% of the 785 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.18 vs. AZN: 1.54 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
AZN' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.81  Med: 1.37 Max: 2.36
Current: 1.54
0.81
2.36
Earnings Yield (Greenblatt) % 4.43
AZN's Earnings Yield (Greenblatt) % is ranked higher than
58% of the 1021 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.62 vs. AZN: 4.43 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
AZN' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 1.5  Med: 11.7 Max: 23.1
Current: 4.43
1.5
23.1
Forward Rate of Return (Yacktman) % -13.51
AZN's Forward Rate of Return (Yacktman) % is ranked lower than
89% of the 367 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.75 vs. AZN: -13.51 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
AZN' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -17.8  Med: 18.4 Max: 27.5
Current: -13.51
-17.8
27.5

More Statistics

Revenue (TTM) (Mil) $23,002
EPS (TTM) $ 1.38
Beta0.68
Short Percentage of Float1.25%
52-Week Range $25.55 - 35.04
Shares Outstanding (Mil)2,530.46

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 22,898 24,456 26,320
EPS ($) 1.77 2.04 2.56
EPS without NRI ($) 1.77 2.04 2.56
EPS Growth Rate
(Future 3Y To 5Y Estimate)
1.41%
Dividends per Share ($) 1.47 1.56 1.66
» More Articles for AZN

Headlines

Articles On GuruFocus.com
Causeway International Value Buys AstraZeneca, Gildan Mar 09 2017 
Dodge & Cox Comments on AstraZeneca Feb 06 2017 
Dodge & Cox's Stock Fund 4th Quarter Commentary Jan 16 2017 
Big Alzheimer Flop Creates Buying Opportunity for Eli Lilly Dec 10 2016 
8 Uncommon Stocks NWQ Managers Is Buying Dec 06 2016 
How Could a Potential Nexium Lawsuit Affect AstraZeneca? Nov 03 2016 
Novo Nordisk Is Being Ignored Oct 06 2016 
Novartis Is Surviving Oct 03 2016 
10 Stocks Dodge & Cox Keep Buying Sep 22 2016 
Dividend and Value Opportunities in the Large-Cap Pharmaceutical Space Apr 05 2016 

More From Other Websites
First Trump Hiccups, Now Brexit Flare-Ups Coming For Stocks Mar 27 2017
Tesaro wins FDA approval for potential blockbuster cancer drug Mar 27 2017
Tesaro Creeps Up On Rivals With Cancer Drug OK, But Merger Unlikely Mar 27 2017
AstraZeneca's Lung Cancer Drug Tagrisso Approved in China Mar 27 2017
AstraZeneca’s Lung Cancer Drug Secures China Approval (AZN) Mar 27 2017
5:48 am AstraZeneca: Tagrisso approved in China as first-in-class treatment for EGFR T790M... Mar 27 2017
Chinese drug approval boosts AstraZeneca's lung cancer hopes Mar 27 2017
Chinese drug approval boosts AstraZeneca's lung cancer hopes Mar 27 2017
Chinese drug approval boosts AstraZeneca's lung cancer hopes Mar 27 2017
Chinese drug approval boosts AstraZeneca's lung cancer hopes Mar 27 2017
AstraZeneca wins approval for lung cancer pill in China Mar 27 2017
New Lung Cancer Drug From AstraZeneca is Approved in China Mar 24 2017
AstraZeneca Stock Rising in '17: What's Working in its Favor? Mar 23 2017
Durvalumab and Tagrisso May Boost AstraZeneca’s Revenues in 2017 Mar 22 2017
How AstraZeneca Controlled Operating Expenses in 2016 Mar 22 2017
Novartis’ Heart Drug Fails Late Stage Trials (NVS, AZN) Mar 22 2017
What Will Drive AstraZeneca’s Oncology Revenues in 2017? Mar 22 2017
Japan May Prove to Be Strong Growth Driver for AstraZeneca in 2017 Mar 21 2017
Why AstraZeneca’s Brilinta Could Become a Blockbuster Drug in 2017 Mar 21 2017
What to Expect from AstraZeneca’s Farxiga in 2017 Mar 21 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)